Drug
Bofanglutide clinical trials
Also written GZR18.
- studies test it
- 25
- open now
- 11
- in phase 3
- 9
- first study started
- 2021
Keep track of what changes. Save the bofanglutide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- GZR18
- 16
Combined with it in one product
Studies by the year they started
25 studies that test it; most in 2025 (9)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 9 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 6
- Phase 3
- 9
What it is tested for
Each study’s main condition, where its own words name it.
- Obesity
- 10
Who runs them
Industry 25 · Other 0
Gan & Lee Pharmaceuticals. (13) · Gan and Lee Pharmaceuticals, USA (10) · Carnot Laboratories (2)
Often tested with
Tested in the same studies.
GZR102 (1) · Metformin (1) · Digoxin (1) · Rosuvastatin (1) · Warfarin (1)
Studies
Open first, then newest update. How each study uses bofanglutide is read from its arms, and is right about nine times in ten.
Testing it · 25
- BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 DiabetesNot yet recruitingPhase 3Carnot LaboratoriesNCT07628985Written as Bofanglutide
- BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or ObesityNot yet recruitingPhase 3Carnot LaboratoriesNCT07622810Written as Bofanglutida
- Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Receiving Positive Airway Pressure (PAP) TherapyNot yet recruitingPhase 3Gan & Lee Pharmaceuticals.NCT07501832Written as GZR18 injection
- Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) TherapyNot yet recruitingPhase 3Gan & Lee Pharmaceuticals.NCT07493057Written as GZR18 injection
- Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight LossRecruitingPhase 3Gan & Lee Pharmaceuticals.NCT07292441Written as GZR18 injection
- Bioequivalence Study of GZR18 Injection Before and After CMC ChangeRecruitingPhase 1Gan & Lee Pharmaceuticals.NCT07355738Written as GZR18 injection A
- Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 InjectionRecruitingPhase 1Gan & Lee Pharmaceuticals.NCT07128888Written as GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets
- Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight SubjectsRecruitingPhase 3Gan & Lee Pharmaceuticals.NCT07150975Written as GZR18
- Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal FunctionRecruitingPhase 1Gan & Lee Pharmaceuticals.NCT07141030Written as GZR18 injection
- Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver FunctionRecruitingPhase 1Gan & Lee Pharmaceuticals.NCT07144098Written as GZR18 injection
- A Phase I Clinical Study to Evaluate the Effect of GZR18 Injection on the Pharmacokinetics of Oral Metformin Hydrochloride Tablets in Overweight/Obese SubjectsNot yet recruitingPhase 1Gan and Lee Pharmaceuticals, USANCT06670209Written as GZR18 and metformin
- Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight ParticipantsCompletedPhase 2Gan and Lee Pharmaceuticals, USANCT06737042Written as GZR18
- A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes MellitusActive, not recruitingPhase 3Gan & Lee Pharmaceuticals.NCT06778967Written as GZR18
- A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight SubjectsActive, not recruitingPhase 3Gan & Lee Pharmaceuticals.NCT06728124Written as GZR18
- A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and ExerciseActive, not recruitingPhase 3Gan & Lee Pharmaceuticals.NCT06777238Written as GZR18
- A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes MellitusActive, not recruitingPhase 2Gan & Lee Pharmaceuticals.NCT07055386Written as GZR18
- The Study of [14C] GZR18CompletedPhase 1Gan & Lee Pharmaceuticals.NCT07119450Written as GZR18 injection、[14C]GZR18 injection
- A Study of GZR18 Injection in Obese/Overweight PatientsCompletedPhase 2Gan and Lee Pharmaceuticals, USANCT06256562Written as GZR18
- A Study of GZR18 Tablet in Chinese Healthy SubjectsActive, not recruitingPhase 1Gan and Lee Pharmaceuticals, USANCT06554054Written as GZR18
- A Phase I Study of GZR18 Injection in Healthy SubjectsCompletedPhase 1Gan and Lee Pharmaceuticals, USANCT06548997Written as GZR18
See all 25 studies that test bofanglutide →
As the comparator · 1 — what is tested is compared with bofanglutide
Codes
What other systems call bofanglutide · ClinicalTrials.gg INT018450
- UNII (FDA) X9RLV48FDHBOFANGLUTIDEOne source FDA
- NCI Thesaurus C206886BofanglutideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | X9RLV48FDH | BOFANGLUTIDE | One source FDA |
| NCI Thesaurus | C206886 | Bofanglutide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.